Aclaris has enough cash to run a busy 2026 immunology catalyst calendar, but the company still has no approved wholly controlled product, recurring operating losses, ATM dilution, and several clinical proof gates that can change the story quickly.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-13 · Company identity, CIK, ticker, exchange, filing sequence, and headquarters.SEC APISEC companyfacts JSON2026-05-13 · XBRL financial fact cross-check support.SEC filingQ1 2026 Form 10-Q2026-05-07 · Latest financial statements, liquidity, ATM financing, R&D program spend, license obligations, and risk context.SEC-filed releaseQ1 2026 earnings release2026-05-07 · Q1 financials, cash runway, ATI-052, bosakitug, ATI-2138, ATI-9494, and 2026 milestone timing.SEC-filed presentationApril 2026 clinical update presentation2026-04-28 · ATI-052 mechanism, PK/PD, target engagement, biologics positioning, and ATI-2138 lichen planus framing.SEC-filed releaseApril 2026 clinical update release2026-04-28 · Full top-line Phase 1a ATI-052 results, ATI-052 Phase 1b/Phase 2b plans, and ATI-2138 lichen planus plan.SEC filingFY2025 Form 10-K2026-02-26 · Business overview, pipeline, KINect platform, competition, regulation, IP, manufacturing, risks, and annual financials.SEC-filed releaseFY2025 results release2026-02-26 · FY2025 financial baseline, cash runway, and 2026 pipeline setup.SEC filingsMarch 2026 ATM financing filings2026-03-09 · At-the-market share sales, gross proceeds, and disclosed institutional buyers.SEC filing2026 proxy statement2026-04-23 · Annual meeting, board nominees, executive officers, beneficial ownership, auditor, and governance disclosures.